BioRegenx, Inc.
BRGX
$0.008
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -31.41% | 154.50% | 319.99% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -31.41% | 154.50% | 319.99% | -- | -- |
| Cost of Revenue | -38.02% | 174.65% | 377.64% | -- | -- |
| Gross Profit | -28.25% | 145.66% | 294.85% | -- | -- |
| SG&A Expenses | 5.33% | 85.30% | 2,784.44% | -- | -- |
| Depreciation & Amortization | -- | 27,391.53% | 17,864.41% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.36% | 150.84% | 1,946.58% | -- | -- |
| Operating Income | -92.16% | -148.86% | -3,693.76% | -- | -- |
| Income Before Tax | -540.39% | -182.47% | -2,315.53% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -540.39% | -182.47% | -2,315.53% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -540.39% | -182.47% | -2,315.53% | -- | -- |
| EBIT | -92.16% | -148.86% | -3,693.76% | -- | -- |
| EBITDA | -27.24% | -61.33% | -3,051.91% | -- | -- |
| EPS Basic | -317.54% | -47.22% | 21.74% | -- | -- |
| Normalized Basic EPS | -32.35% | -50.00% | 23.61% | -- | -- |
| EPS Diluted | -317.54% | -47.22% | 21.74% | -- | -- |
| Normalized Diluted EPS | -32.35% | -50.00% | 23.61% | -- | -- |
| Average Basic Shares Outstanding | 42.16% | 20.14% | 35.50% | -- | -- |
| Average Diluted Shares Outstanding | 42.16% | 20.14% | 35.50% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |